Researchers have identified a new biomarker and potential master regulator of tumorigenesis and drug resistance in Hepatocellular Carcinoma (HCC).
Maina Team publishes in Journal of Hepatology. The team found that ADAMTSL5 is an epigenetically activated oncogene overexpressed in a large fraction of human HCC patients and in HCC mouse models.